Key result
Drug-eluting balloons resulted in a smaller minimal lumen diameter at 9 months compared to everolimus-eluting stents.
Why the study?
Treatment of patients with bare-metal stent in-stent restenosis remains a challenge and requires comparison of drug-eluting balloons versus everolimus-eluting stents.
Does paclitaxel-eluting balloon improve minimal lumen diameter compared to everolimus-eluting stent in patients with bare-metal stent in-stent restenosis?
RCT (n=189)
Yes
Does paclitaxel-eluting balloon improve minimal lumen diameter compared to everolimus-eluting stent in patients with bare-metal stent in-stent restenosis?
Answers are grounded in this paper and cite their sources.
In patients with bare-metal stent in-stent restenosis, everolimus-eluting stents provide superior late angiographic findings compared to paclitaxel-eluting balloons, though both yield excellent clinical results.
OBJECTIVES: This study sought to compare the efficacy of drug-eluting balloons (DEB) with that of everolimus-eluting stents (EES) in patients with bare-metal stents (BMS) in-stent restenosis (ISR). BACKGROUND: Treatment of patients with ISR remains a challenge. METHODS: This was a prospective, multicenter, randomized trial comparing DEB with EES in patients with bare-metal stents (BMS) in-stent restenosis (ISR). The primary endpoint was the minimal lumen diameter at 9 months' follow-up. RESULTS: A total of 189 patients with BMS-ISR from 25 Spanish sites were included (95 were allocated to DEB and 94 to EES). Procedural success was achieved in all patients. At late angiography (median 249 days; 92% of eligible patients), patients in the EES arm had a significantly larger minimal lumen diameter (2.36 ± 0.6 mm vs. 2.01 ± 0.6 mm, p < 0.001; absolute mean difference: 0.35 mm; 95% confidence interval [CI]: 0.16 to 0.53) and a lower percent of diameter stenosis (13 ± 17% vs. 25 ± 20%, p < 0.001). However, late loss (0.04 ± 0.5 mm vs. 0.14 ± 0.5 mm, p = 0.14) and binary restenosis rate (4.7% vs. 9.5%, p = 0.22) were very low and similar in both groups. Clinical follow-up (median 365 days) was obtained in all (100%) patients. Occurrences of the combined clinical outcome measure (cardiac death, myocardial infarction, and target vessel revascularization; 6% vs. 8%; hazard ratio [HR]: 0.76; 95% CI: 0.26 to 2.18, p = 0.6) and the need for target vessel revascularization (2% vs. 6%; HR: 0.32: 95% CI: 0.07 to 1.59, p = 0.17) were similar in the 2 groups. CONCLUSIONS: In patients with BMS-ISR, both DEB and EES provided excellent clinical results with a very low rate of clinical and angiographic recurrences. However, compared with DEB, EES provide superior late angiographic findings. (Restenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting Balloon vs. Everolimus-eluting Stent [RIBS V]; NCT01239953).
No takes yet. Share an insight, caveat, or question.
Alfonso et al. (2014) conducted an RCT in Bare-metal stent in-stent restenosis (n=189). Drug-eluting balloons (DEB) vs. Everolimus-eluting stents (EES) was evaluated on Minimal lumen diameter at 9 months' follow-up (MD 0.35, 95% CI 0.16 to 0.53, p=<0.001). Drug-eluting balloons resulted in a smaller minimal lumen diameter at 9 months compared to everolimus-eluting stents.
Synapse has enriched 10 related papers. Consider them for comparative context: